E-viri
PDF
Recenzirano
Odprti dostop
-
Grosshans, David R
Lancet oncology/Lancet. Oncology, 03/2016, Letnik: 17, Številka: 3Journal Article
Some researchers have argued that the biological uncertainties associated with proton therapy could lead to more disease recurrences in patients with medulloblastoma.2 With 5-year progression-free survival of 85% (95% CI 69-93) for patients with standard-risk disease and 70% (45-85) for those with high to intermediate risk disease, Torunn Yock and colleagues1 recorded similar disease control to that reported in large cooperative group studies of photon-based treatment.3,4 Coupling this finding with a detailed analysis of the patterns of failure, the investigators quell concerns regarding disease recurrence.
